07:00 , May 30, 2011 |  BioCentury  |  Emerging Company Profile

QR: Power of positivity

QR Pharma Inc. has in-licensed a pair of compounds for cognitive impairment and Alzheimer's disease it believes have suffered from neglect rather than a lack of efficacy or safety. The more advanced of the two...
07:00 , Apr 30, 2007 |  BC Week In Review  |  Company News

Curidium board of directors update

Curidium Medica plc (LSE:CUR), London, U.K.   Business: Neurology   Retiring: Non-executive Chairman Simon Cartmell on May 23; he will be succeeded by Gosse Bruinsma, former president and CEO of Axonyx Inc. , as executive...
07:00 , Oct 9, 2006 |  BC Week In Review  |  Company News

Pharmos management update

Pharmos Corp. (PARS), Iselin, N.J.   Business: Neurology   Hired: S. Colin Neill as SVP, CFO, secretary and treasurer, formerly CFO at Axonyx Inc.; he replaces James Meer, who is departing  ...
07:00 , Oct 9, 2006 |  BC Week In Review  |  Company News

Axonyx, TorreyPines deal

The companies completed their previously announced reverse-merger to form TorreyPines Therapeutics Inc. (see BioCentury, June 12). The company trades on NASDAQ under the symbol TPTX. Axonyx Inc. (AXYX), New York, N.Y.   TorreyPines Therapeutics Inc....
00:42 , Oct 6, 2006 |  BC Extra  |  Company News

Pharmos names Neill CFO

Neurology company PARS hired S. Colin Neill as SVP and CFO. Previously, Neill was CFO of Axonyx (AXYX). He replaces James Meer. On Thursday, PARS was unchanged at $1.75....
07:00 , Sep 25, 2006 |  BC Week In Review  |  Company News

NovaDel board of directors update

NovaDel Pharma Inc. (NVD), Flemington, N.J.   Business: Drug delivery   Appointed: Steven Ratoff as chairman; chairman of Axonyx Inc. and a venture partner with ProQuest Investments; he replaces NVD President and CEO Jan Egberts,...
07:00 , Jun 12, 2006 |  BC Week In Review  |  Company News

Axonyx, TorreyPines deal

TorreyPines and AXYX will reverse-merge to form TorreyPines Therapeutics Inc. , which is expected to trade on NASDAQ under the symbol TPTX. The newco will focus on migraine, chronic pain and Alzheimer's disease (AD). TorreyPines...
00:14 , Jun 9, 2006 |  BC Extra  |  Top Story

TorreyPines, Axonyx to reverse-merge

TorreyPines (La Jolla, Calif.) and AXYX will reverse-merge to form TorreyPines Therapeutics Inc. , which is expected to trade on NASDAQ under the symbol TPTX. The newco will focus on migraine, chronic pain and Alzheimer's...
07:00 , May 22, 2006 |  BC Week In Review  |  Clinical News

Posiphen: Phase I data

Data from a double-blind, placebo-controlled Phase I trial in 48 patients showed that the mean Posiphen blood levels associated with well tolerated doses in humans are higher than blood Posiphen levels which showed potentially beneficial...
07:00 , May 1, 2006 |  BC Week In Review  |  Clinical News

Axonyx preclinical data

In a mouse model of AD, pre-treatment of animals with Posiphen increased the ability of transplanted human neuronal stem cells (HNSCs) to differentiate into neurons in the brain areas where they were needed. HNSCs did...